To Top

Issue:

Q4 2017

13 Articles available
Cell and Gene Therapy

Segregation in the Design of Gene Therapy Manufacturing Facilities

PAP-Q4-17-CL-002
Regulatory

No Clinically Meaningful Difference: The Upward Trend of Biosimilars

PAP-Q4-17-FA-001
Nice Insight Overview

From Digitalization to Nanoscale Delivery: Emerging Technologies Are Driving the Future of Pharma

PAP-Q4-17-NO-001
Clinical Trials

Managing the Complexities of Outbound Clinical Drug Distribution

PAP-Q4-17-CL-001
Biologics

ADCs: The Future of Biologic Drugs

PAP-Q04-17-VP-001
API

Right-First-Time Innovation Approach Drives Continual Investment

PAP-Q4-17-CL-003
Innovation

Moving Beyond Monoclonal Antibodies

PAP-Q4-17-FA-002
Automation

Pharma’s Automation Index on the Rise

PAP-Q4-17-FA-003
Innovation

Developing Targeted Potassium Channel Openers for CNS-Related Therapeutics

PAP-Q4-17-CL-004
API

Achieving Efficient Pharmaceutical Synthesis with Process Intensification

PAP-Q3-17-CL-003
Innovation

Single-Use Operational Excellence Explained: Effective Lifecycle Management

PAP-Q4-17-CL-006
Roundtable

Q: Looking forward, what technologies do you anticipate having the greatest impact in 2018?

PAP-Q4-17-RT-002
//Fix for text overflow in cards